This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhattacharyya, S. Articles by Caplin, M. E. Search for Related Content PubMed PubMed Citation Articles by Bhattacharyya, S. Articles by Caplin, M. E. Related Collections Valvular heart disease

(Circulation. 2007;116:2860-2865.)
© 2007 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Carcinoid Heart Disease

Sanjeev Bhattacharyya, MB, ChB, MRCP; Joseph Davar, MD, PhD; Gilles Dreyfus, MD, FRCS; Martyn E. Caplin, BSc (Hons), DM, FRCP

From the Carcinoid Heart Disease Clinic, Department of Cardiology (S.B., J.D.), and Neuroendocrine Tumour Unit (M.E.C.), Royal Free Hospital, and Department of Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust (G.D.), London, UK.

Correspondence to Dr Joseph Davar, Carcinoid Heart Disease Clinic, Department of Cardiology, Royal Free Hospital, Pond St, London, NW3 2QG, UK. E-mail joseph.davar@royalfree.nhs.uk

Key Words: carcinoid heart disease • heart diseases • valves

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Carcinoid tumors are relatively rare neuroendocrine malignancies most commonly originating from enterochromaffin cells in the gastrointestinal tract. The incidence is 1 in 100 000 of the general population.¹ They usually grow slowly over years, commonly causing no symptoms at all until they become large or have metastasized. Carcinoid tumors of midgut origin may secrete large amounts of vasoactive substances, including 5-hydroxytryptamine (5-HT), tachykinins, and prostaglandins. These are largely inactivated by the liver. Carcinoid syndrome occurs when tumor cells metastasize to the liver as the vasoactive substances produced are able to reach the systemic circulation via the hepatic vein. Clinically, this is characterized by flushing, diarrhea, and bronchospasm.

Over the past decade, several new therapies for carcinoid tumors have emerged to reduce symptoms and cause tumor regression. Most notably, the development of somatostatin analogs, which inhibit the release of various biogenic amines and peptides, including serotonin, has resulted in a marked improvement in symptoms.² These may also have contributed to increased survival, although this has not been proved.^2,3 Rarely, surgical resection is curative for nonmetastatic disease. Otherwise, reduction of symptoms, improvement in quality of life, and improvement in survival by inhibition of tumor hormones or reduction of tumor load are the main goals. Metastatic disease of the liver may be debulked either surgically or by hepatic artery embolization in selected patients. Interferon therapy and targeted radionuclide therapy may stabilize or reduce the tumor. Chemotherapy is rarely an option except for pancreatic, bronchial, and high-grade neuroendocrine tumors.

Carcinoid heart disease (CHD) was . . . [Full Text of this Article]

This article has been cited by other articles:

				R. A. Pena-Silva, J. D. Miller, Y. Chu, and D. D. Heistad Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1354 - H1360. [Abstract] [Full Text] [PDF]

				S. R. Raj, C. M. Stein, P. J. Saavedra, and D. M. Roden Cardiovascular Effects of Noncardiovascular Drugs Circulation, September 22, 2009; 120(12): 1123 - 1132. [Full Text] [PDF]

				H. u. Rehman Carcinoid syndrome Can. Med. Assoc. J., June 23, 2009; 180(13): 1329 - 1329. [Full Text] [PDF]

				S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp Role of echocardiography in toxic heart valvulopathy Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476. [Abstract] [Full Text] [PDF]

				K. A. Mizuguchi, A. A. Fox, T. M. Burch, L. H. Cohn, and J. A. Fox Tricuspid and Mitral Valve Carcinoid Disease in the Setting of a Patent Foramen Ovale Anesth. Analg., December 1, 2008; 107(6): 1819 - 1821. [Full Text] [PDF]

				H.-B. Fiebrich, A. H. Brouwers, T. P. Links, and E. G.E. de Vries Myocardial Metastases of Carcinoid Visualized by 18F-Dihydroxy-Phenyl-Alanine Positron Emission Tomography Circulation, October 7, 2008; 118(15): 1602 - 1604. [Full Text] [PDF]